A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and less severe, exacerbations and had ...
Hosted on MSN
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma
Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now. On June 27, Viatris received approval from China’s National Medical Products Administration/NMPA for Yupelri ...
Approval triggers $7.5 million milestone payment from Viatris, with eligibility to receive further sales milestones and tiered royalties on net sales in China Ampreloxetine, an investigational, ...
DUBLIN, Feb. 26, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced financial and operational results for the fourth quarter of 2023 and ...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today ...
For individuals living with COPD, small changes may make a difference. Viatris Inc. and Theravance Biopharma US, Inc. COPD, or chronic obstructive pulmonary disease, is a group of life-changing lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback